Location History:
- Epsom, GB (2010 - 2014)
- Cambridge, GB (2018)
Company Filing History:
7 out of 23 
3 out of 541 
2 out of 2 Years Active: 2010-2018
Title: David Gareth Williams: A Pioneer in Antibody Innovation
Introduction
David Gareth Williams, a distinguished inventor based in Epsom, GB, has made significant contributions to the field of biotechnology through his innovative work in antibody development. With a remarkable portfolio consisting of 11 patents, he continues to push the boundaries of medical research and therapeutic applications.
Latest Patents
Among his latest patents is the groundbreaking work on **humanized anti-Tn-MUC1 antibodies** and their conjugates. This patent details conjugates comprising pyrrolobenzodiazepines (PBDs) that feature a labile protecting group, enhancing the efficacy of the antibody in therapeutic contexts. Additionally, his patent on **humanized anti-CD22 antibodies** showcases advanced techniques in developing chimeric and humanized versions of the anti-CD22 mouse monoclonal antibody, HB22.7. This invention focuses on utilizing these antibodies for treating various conditions, including oncology, transplantation, and autoimmune diseases, emphasizing their role in mediating human antibody-dependent cellular cytotoxicity (ADCC) and other immune responses.
Career Highlights
David has held prominent positions in influential companies such as **Lpath, Inc.** and **Medimmune Limited**. His career has been marked by an unwavering commitment to innovation, particularly in therapeutic strategies aiming to combat serious health challenges.
Collaborations
Throughout his career, David has collaborated with talented individuals, including notable coworkers Roger A. Sabbadini and William A. Garland. Their collective expertise has contributed to a rich environment for innovation, driving advancements in antibody research and development.
Conclusion
David Gareth Williams stands out as a key figure in the realm of biotechnology, demonstrating a significant impact through his extensive patent portfolio and collaborative endeavors. His work in developing humanized antibodies is reshaping therapeutic options, ultimately contributing to improved patient outcomes in various medical fields.